logo-loader

Valeo Pharma gets approval from Health Canada to sell its immune support Hesperco capsules

Published: 13:58 03 Sep 2020 EDT

 Valeo Pharma Inc (CSE:VPH) CEO Steve Saviuk tells Proactive it has received a natural product license approval from Health Canada authorizing the sale of its for its citrus bioflavonoid formulation named Hesperco in Canada.

Saviuk says the group can now begin the commercial launch of Hesperco capsules and it is anticipating product availability by end of September 2020.

Valeo Pharma Q1 numbers shows asthma product revenues increasing by 58%

Valeo Pharma CEO Steve Saviuk joined Steve Darling from Proactive to discuss the company's financial results for the first quarter ended January 31, 2024. Valeo Pharma reported revenues of $13.5 million in Q1-24, compared to $13.1 million in Q1-23 and $13.1 million in Q4-23, representing a 3%...

1 week, 3 days ago